Skip to content

Study · Non-randomized trial · 2014

10 results

Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T

Journal of bone and mineral metabolism9 Nov 2013Cited by 25 (Europe PMC)

PMID24213216 (opens in a new tab)DOI10.1007/s00774-013-0505-2 (opens in a new tab)PepBankPUB-24213216
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese osteoporosis patients aged <75 years, teriparatide reduced vertebral fracture risk versus placebo (RR 0.06).

    In plain wordsIn patients aged <75 years, teriparatide reduced spine fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fracture risk below age 75
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.06 RR
    age <75 years, teriparatide versus placebo

    Source sentences

    Summary
    Significant fracture risk reductions were observed in the subgroups of individuals aged <75 years [relative risk (RR) 0.06, p = 0.007] and ≥75 years (RR 0.32, p = 0.015).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese osteoporosis patients aged ≥75 years, teriparatide reduced vertebral fracture risk versus placebo (RR 0.32).

    In plain wordsIn patients aged ≥75 years, teriparatide reduced spine fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fracture risk at age 75 or above
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.32 RR
    age >=75 years, teriparatide versus placebo

    Source sentences

    Summary
    Significant fracture risk reductions were observed in the subgroups of individuals aged <75 years [relative risk (RR) 0.06, p = 0.007] and ≥75 years (RR 0.32, p = 0.015).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteoporosis patients with 1 prevalent vertebral fracture, teriparatide reduced fracture risk versus placebo (RR 0.08).

    In plain wordsWith 1 existing spine fracture, teriparatide reduced fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk with one prevalent vertebral fracture
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.08 RR
    1 prevalent vertebral fracture, teriparatide versus placebo

    Source sentences

    Summary
    A significant risk reduction was observed among patients with prevalent vertebral fracture in the subgroup with 1 (RR 0.08, p = 0.015) or ≥2 (RR 0.29, p = 0.009) prevalent vertebral fractures, and in those with grade 3 deformity (RR 0.26, p = 0.003).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  4. 04HumanNon-randomized trialEfficacy outcome

    In osteoporosis patients with ≥2 prevalent vertebral fractures, teriparatide reduced fracture risk versus placebo (RR 0.29).

    In plain wordsWith ≥2 existing spine fractures, teriparatide reduced fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk with multiple prevalent vertebral fractures
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.29 RR
    >=2 prevalent vertebral fractures, teriparatide versus placebo

    Source sentences

    Summary
    A significant risk reduction was observed among patients with prevalent vertebral fracture in the subgroup with 1 (RR 0.08, p = 0.015) or ≥2 (RR 0.29, p = 0.009) prevalent vertebral fractures, and in those with grade 3 deformity (RR 0.26, p = 0.003).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  5. 05HumanNon-randomized trialEfficacy outcome

    In osteoporosis patients with grade 3 deformity, teriparatide reduced fracture risk versus placebo (RR 0.26).

    In plain wordsWith grade 3 spine deformity, teriparatide reduced fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk with grade 3 deformity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.26 RR
    grade 3 deformity, teriparatide versus placebo

    Source sentences

    Summary
    A significant risk reduction was observed among patients with prevalent vertebral fracture in the subgroup with 1 (RR 0.08, p = 0.015) or ≥2 (RR 0.29, p = 0.009) prevalent vertebral fractures, and in those with grade 3 deformity (RR 0.26, p = 0.003).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  6. 06HumanNon-randomized trialEfficacy outcome

    In osteoporosis patients with lumbar BMD < -2.5 SD, teriparatide reduced fracture risk versus placebo (RR 0.25).

    In plain wordsWith lumbar BMD < -2.5 SD, teriparatide reduced fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk with low lumbar BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Measurements

    Relative risk of vertebral fracture
    0.25 RR
    lumbar BMD < -2.5 SD, teriparatide versus placebo

    Source sentences

    Summary
    Significant risk reduction was observed in the subgroup with lumbar bone mineral density (BMD) < -2.5 SD (RR 0.25, p = 0.035).
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  7. 07HumanNon-randomized trialEfficacy outcome

    In teriparatide-treated osteoporosis patients without prevalent vertebral fractures, no incident fracture occurred.

    In plain wordsNo new fracture occurred in teriparatide-treated patients without an existing spine fracture.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableIncident fractures without prevalent fractures
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    In the teriparatide group, no incident fracture was observed in the subgroups with a prevalent vertebral fracture number of 0, with grade 0-2 vertebral deformity, or with lumbar BMD ≥2.5 SD.
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  8. 08HumanNon-randomized trialEfficacy outcome

    In teriparatide-treated osteoporosis patients with grade 0-2 vertebral deformity, no incident fracture occurred.

    In plain wordsNo new fracture occurred in teriparatide-treated patients with grade 0-2 spine deformity.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableIncident fractures with grade 0-2 deformity
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    In the teriparatide group, no incident fracture was observed in the subgroups with a prevalent vertebral fracture number of 0, with grade 0-2 vertebral deformity, or with lumbar BMD ≥2.5 SD.
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  9. 09HumanNon-randomized trialEfficacy outcome

    In teriparatide-treated osteoporosis patients with lumbar BMD ≥2.5 SD, no incident fracture occurred.

    In plain wordsNo new fracture occurred in teriparatide-treated patients with lumbar BMD ≥2.5 SD.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableIncident fractures with higher lumbar BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    In the teriparatide group, no incident fracture was observed in the subgroups with a prevalent vertebral fracture number of 0, with grade 0-2 vertebral deformity, or with lumbar BMD ≥2.5 SD.
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections
  10. 10HumanNon-randomized trialEfficacy outcome

    In Japanese osteoporotic patients, once-weekly teriparatide reduced vertebral fracture risk versus placebo in all bone turnover marker and estimated glomerular filtration rate subgroups.

    In plain wordsTeriparatide reduced spine fracture risk versus placebo across all bone turnover marker and kidney function subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fracture risk across bone turnover marker and eGFR subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Significant risk reduction was observed in all of the bone turnover marker and estimated glomerular filtration rate subgroups.
    2 context sentences
    Summary · context
    Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups.
    Summary · context
    once-weekly 56.5 μg teriparatide injection reduced the vertebral fracture risk in patients with varying degrees of fracture risk, age, vertebral fracture number and grade, bone turnover level, and renal function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.